Business Wire

APR Applied Pharma Research S.A. and Eris Pharmaceuticals (Australia) Pty Ltd. Announce the Signature of a License Agreement for the Distribution and Marketing of the HALYKOO Line in Australia and New Zealand

Del

APR Applied Pharma Research S.A. (“APR”), the independent Swiss company, specialized in the development of science-driven, patent-protected healthcare products, and Eris Pharmaceuticals (Australia) Pty Ltd. (“Eris Pharma”), a leading pharmaceutical company, currently specialized in the development and marketing of healthcare products in Australia and the emerging markets, today announce the beginning of a partnership for the promotion, distribution and marketing of the Halykoo baby healthcare product line in Australia and New Zealand.

Thanks to this license agreement, APR records another success in widening its global network of partners for the brand Halykoo, which has been recently launched in Italy and will be rolled out in 2016 in several countries across the world, proving Halykoo high level of quality, innovation and appeal on an international basis.

This partnership will enable Eris Pharma to enter the pediatric market segment through the offer of the new and innovative brand, Halykoo - the first complete line of products including tailor-made therapeutic solutions, designed and developed for children’s health and wellbeing since newborns.

“We are proud to have the chance to launch the Halykoo range in Australia and New Zealand” – said Mr. Panos Athanasiou, CEO of Eris Pharma. “The HALYKOO brand will complement consistently the product portfolio of Eris Pharma, that currently covers a wide range of prescription medicine, OTC products, Medical Devices and skincare products, most of which are mainly addressed to adults. Adding the Halykoo products in our portfolio will enable us to bring to the Australian & New Zealand markets products targeting currently unaddressed needs of children from a very young age, providing the needed confidence and reassurance to their parents .

Eris Pharma Sales Director Mr. Karl Hansen asserted that “Halykoo represents a great opportunity to successfully compete in as valuable an area of the market as pediatric healthcare. Australian parents spend many billions of dollars each year ensuring the healthcare needs of their children are met, but are often confused in a congested marketplace. At the same time they are concerned about the ingredients in the products they buy, which is why the Halykoo range offers unique, innovative products that parents can trust. Eris Pharma is very excited to introduce Halykoo to Australian parents and is looking forward to playing a continuing role in their children’s health.”

Over the last 20 years, APR has developed high-quality products certified according to the strictest international regulations. “We are delighted to hail this partnership with Eris Pharma, which allows APR to enter new attractive overseas markets, Australia and New Zealand, and proves Halykoo internationally valuable positioning and potential” said Paolo Galfetti, CEO and co-founder of APR”. “We reckon that Eris Pharma is the right partner to introduce to caregivers and consumers an innovative and unique product option as Halykoo”.

About Halykoo

Halykoo is a new global brand in the pediatric self-care market, conceived and developed by APR starting from an unmet demand driven insight, which aims to transform the moments of child healthcare in a time of relation (between mother and kid) peaceful, simple and safe in order to get parents’ confidence and smiling babies.

Halykoo is the first and only OTC pediatric healthcare brand that matches formulations specifically focused on each of the unique ages and stages of children’s growth, since birth, with smart and innovative formulations and delivery systems intended to simplify their use for parents and reduce the hassle for babies.

Halykoo products are the perfect combination of responsible, Swiss, high-quality research combined with an extensive understanding of child and caregivers needs: as a result, each Halykoo product provides the right formula – from accurate selection of the ingredients (including natural BIO certified components), to careful dosing of the active principles and full compliance with the strictest safety standards - and the right delivery system for the right age.

For more info about Halykoo, please visit: www.halykoo.com

About Eris Pharmaceuticals (Australia) Pty Ltd

Eris Pharmaceuticals (Eris Pharma) was established in Australia in 2009 as a generic pharmaceuticals company. Today, Eris Pharma is an international leader in developing and distributing premium quality healthcare products in the generics, dermocosmetics, OTC and medical device categories. Eris Pharma’s focus is on premium products in numerous therapeutic categories that contain only the highest quality ingredients in specialised formulations.

Eris Pharma distributes its products to over 25 markets worldwide and has an aggressive plan to grow the business, focusing heavily on the Australian market. Underlying this ambition is Eris Pharma’s desire to form strong relationships that deliver only the best possible outcomes for customers and end users.

For more info about Eris Pharmaceuticals, please visit www.eris-pharma.com.au.

About APR Applied Pharma Research s.a.

APR is an independent Swiss company, specialized in the development of science-driven, patent-protected healthcare products. The Company identifies, develops and licenses science- driven, value-added products designed to address patient or consumer needs in selected therapeutic areas on a global basis. Specifically, APR is currently focused on 2 (two) major areas: (i) internally developed and financed (alone or with our co-development partners) proprietary, value-added products to be licensed to healthcare companies for their commercialization, and (ii) support to third-party projects, by offering value-added, R&D services under contract and fee for service arrangements. APR has a balanced pipeline of revenue-generating branded products marketed in all major markets, combined with a compelling pipeline of products at different development stages. APR has entered into licensing and partnership agreements with pharmaceutical companies in over 70 countries, with international sales on a worldwide basis. For more info, please visit: www.apr.ch.

Contact information

Eris Pharmaceuticals (Australia) Pty Ltd
Panos Athanasiou; Chief Executive Officer
T.: +61 4 14143678 or email to p.athanasiou@eris-pharma.com
or
Karl Hansen; Sales Director - Australia and New Zealand
T.: +61 4 17062642 or email to k.hansen@eris-pharma.com
or
APR Applied Pharma Research s.a.
Paolo Galfetti; Chief Executive Officer
T: +41 91 6957020 or email to paolo.galfetti@apr.ch

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Huawei Brings the All-Connected World to Mobile World Congress25.2.2018 13:30Pressemelding

Building on its success in delivering beautifully-designed and powerful high-end mobile devices, Huawei Consumer Business Group (CBG) today unveiled the HUAWEI MateBook X Pro, the HUAWEI MediaPad M5 Series and the HUAWEI 5G customer-premises equipment (CPE), the world’s first commercial terminal device supporting the globally recognized 3GPP telecommunications standard for 5G. With stunning new design updates and outstanding performance advances, Huawei’s new devices showcase the power of technology to deliver innovative computing experiences ready for the mobile world. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180225005135/en/ MateBook X Pro (Photo: Business Wire) “At Huawei, we’re guided by a vision of an all-connected world, and to achieve that goal, we invest significantly in research and development to understand the ways in which people interact and connect with technology,” said Richard Yu, CEO of Huawei CBG. “We’

The 6th Annual World Patient Safety, Science & Technology Summit Kicked off with an Important Announcement about the Progress Being Made to Save Lives in Hospital Settings24.2.2018 10:00Pressemelding

The 6th Annual World Patient Safety, Science & Technology Summit kicked off with an important announcement about the progress being made to save lives in hospital settings. Nearly 4,600 hospitals in 44 countries have committed to adopting patient safety processes that are proven to eliminate preventable deaths in hospitals. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180224005027/en/ England’s Health and Social Care Secretary, Rt. Hon. Jeremy Hunt, launches groundbreaking new measures on Day One of the 6th Annual World Patient Safety, Science & Technology held in London (Photo: Business Wire) The Patient Safety Movement Foundation has taken on an inspiring and ambitious goal of reducing preventable patient deaths in hospitals to ZERO by 2020. The annual Summit in central London plays a major role in taking on that challenge with the participation of 300 global leaders, medical experts, medical technology CEOs, and patient

WuQi Technologies is Latest Licensee of CCww’s NB-IoT UE Protocol-Stack Software24.2.2018 09:06Pressemelding

Communications Consultants Worldwide Ltd. (CCww), global innovator of 3GPP® technologies, has licensed its NB-IoT protocol-stack software to WuQi Technologies Inc., a leading global developer of highly integrated mixed-signal SoC solutions, and the latest licensee of CCww’s NB-IoT Release 13 UE protocol-stack software. Communications Consultants Worldwide (CCww) is working with WuQi Technologies for the integration of its NB-IoT protocol-stack software onto WuQi Technologies’ highly innovative SoC. This relationship, catalyzed by T2M, is enabling the production of a highly integrated, very low power, NB-IoT SoC chipset targeting IoT Smart City, Smart Home, and wearable applications. CCww’s CEO, Richard Carter, said, “NB-IoT is CCww’s latest cellular Protocol-stack SW. We are excited to be working with WuQi to enable a sector-leading NB-IoT SoC, pushing back boundaries of performance and battery life for the next generation of IoT. See our demonstration at the Mobile World Congress (Hal

IDEMIA and Octo Telematics Reinvent Car Sharing Experience by Adding Facial Recognition to EasyOpen Solution23.2.2018 15:57Pressemelding

IDEMIA, the global leader in Augmented Identity for an increasingly digital world, announces today that it has implemented facial recognition technology on EasyOpen, a solution previously developed with its partner Omoove, a wholly-owned Octo Telematics company, Europe’s leading Shared Mobility technology provider. The digital enrolment process combined with facial recognition technology will securely enroll and authenticate the driver before EasyOpen automatically opens the car. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180223005506/en/ (Photo: Idemia) You will never rent a car the same way thanks to EasyOpen solution that combines IDEMIA’s expertise in secure service enablement and Omoove’s experience in Shared Mobility platforms and on-board technology. The first version of the solution was launched last year and allows drivers, who have already registered on the application, to use their smartphones as a key to open

SM-Optics Unveils First FLEXSET Chip, Paving the Way to Optical Micro Nodes23.2.2018 14:00Pressemelding

SM-Optics launches FLEXSET, a single chip embedding multiple processing functionalities raising the bar for performances, density and architectural flexibility. The FLEXSET is the heart of the Lightmode product family. FLEXSET OTN switching matrix scales from 300Gbps to 1Tbps and can be addressed by ports spanning from traditional low-speed services like 2Mbps over micro-OTN, to layer2 and layer3 over ODUFlex, 100G over ODU4 and 200G over FlexO. Thanks to its embedded capabilities including multi-technology OAM, packet processing, synchronization and fast protection functions, FLEXSET operates by design at the lowest latency performances and features an Intel Stratix 10 FPGA. Following the launch of micro-OTN, a revolutionary approach to efficiently extend OTN protocol to low speed services, the launch of FLEXSET advances the vision of a highly interconnected metro network and of micro nodes. Revolving around functional block elements, micro nodes collapse in few rack units OTN and pho

Bitcoin Miner HashGains’ Crowdsale to Build Green Cloud Mining Data Centers Receives Excellent Response23.2.2018 13:56Pressemelding

HashGains.com, a leading cryptocurrency mining platform, has launched its crowdsale program to build mega cryptocurrency cloud mining data centers in India and Canada which uses renewable energy like wind and solar as source of energy. “With the growing worries around bitcoin mining causing environmental damage, difficulty levels of mining increasing and returns heading southwards, there was no better opportunity but to build green energy data centers which run on free sources of energy like wind and solar, ensuring handsome mining rewards while taking care of environment,” said Mr Anuj Bairathi, CEO & Founder, HashGains, who is crypto enthusiast himself. HashGains is a growing cloud mining platform with more than 10,000 active customers enjoying mining returns and is expected to reach the mark of 1 million customers by 2020. To handle such a massive growth and ever growing demand of customers, it becomes even more important that mega mining centers are planned which can serve needs of